Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)

StatusCompleted
PhasePhase 3
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv9
  2. Study Identification, Study Status, Sponsor/Collaboratorsv8
  3. Trial status: Active, Not Recruiting to Completed
    • Primary and study completion dates: Nov 2008
    v7
  4. Study title expanded, about 1 wordv6
  5. Re-verified, no change to tracked fieldsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v4
  2. 2 versions Re-verified since Jan 16, 2006, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Osteopenia and osteoporosis are being described more frequently in people with HIV infection. This study will test the efficacy of alendronate in comparison with a placebo after 2 years, in people with primary osteoporosis. People will receive the recommended adequate intake of calcium and vitamin D.
Trial Details
NCT Number NCT00120757
Lead Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Conditions
(from sponsor)		 Osteoporosis, HIV Infections
Related terms HIV Infections, Osteoporosis
Enrollment 140 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov